Aurobindo Pharma, a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients headquartered at Hyderabad, received final approval from the US Food and Drug Administration (USFDA) for cefazolin for Injection USP 500 mg.vial and 1 gram/vial.
This is a sterile cephalosporin product under the anti-nfective segment and generic equivalent to Abraxis Pharmaceutical Products' Reference Listed drug Cefazolin for injections USP 500 mg.vial and 1 gram /vial. This is the third product approval by the USFDA for the sterile injectable formulation line of Unit VI-B, situated in Hyderabad. Aurobindo now has 74 abbreviated new drug applications (ANDAs) approved by the USFDA, according to a press release.
